This study focuses on patients with Stage IV Non-small Cell Lung Cancer (NSCLC) who have already received previous treatments. The study evaluates three different medications: Ifinatamab Deruxtecan (also known as MK-2400), Raludotatug Deruxtecan (also known as MK-5909), and Docetaxel. These medications are given through intravenous infusion, which means they are administered directly into a vein.

The purpose of this research is to evaluate how well these treatments work in treating advanced non-squamous non-small cell lung cancer and to assess their safety. The study specifically includes patients whose cancer has progressed after receiving both platinum-based chemotherapy and immunotherapy treatments. The treatment period may last up to 24 months, during which patients will receive regular doses of one of the study medications.

Throughout the study, participants will undergo regular medical evaluations to monitor their response to treatment and any side effects. The research team will track various aspects of the participants’ health, including how the tumor responds to treatment, how long the response lasts, and how long patients survive without their disease getting worse. The study will use specialized imaging to measure changes in tumor size and assess the effectiveness of the treatment.